News | May 07, 2021
Lonza announces expansion plans for mammalian manufacturing facilities
The facility is expected to be completed in 2024
The facility is expected to be completed in 2024
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The vaccine was 85 percent effective in preventing severe disease across all regions.
Bharat Biotech expects to share further details of the trial results as additional data become available.
The company will review FDA's response and decide on appropriate next steps soon.
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Subscribe To Our Newsletter & Stay Updated
